Senti Biosciences executive sells $6,074 in stock

Rajangam Kanya, President and Chief Medical (TASE:PMCN) and Development Officer at Senti Biosciences, Inc. (NASDAQ:SNTI), a micro-cap biotech company with a market capitalization of approximately $20 million, sold a total of 1,479 shares of common stock in two separate transactions, according to a recent SEC filing. The company’s stock has shown significant volatility, having rallied over 174% in the past six months. The sales, which took place on February 4 and February 6, were executed at prices ranging from $4.07 to $4.37 per share, amounting to a total value of $6,074.

Following these transactions, Kanya retains ownership of 8,621 shares in the company. The sales were conducted under a "sell-to-cover" policy, a standard procedure to cover tax withholding obligations related to the vesting of restricted stock units, and were automatic rather than discretionary.

In other recent news, Senti Biosciences has been making significant strides in its operations. The company’s Interim Chief Financial Officer, Yvonne Li, transitioned to a consulting role, ensuring a smooth transfer of her responsibilities until March 31, 2025. The company has yet to announce a successor for the CFO position.

In the financial realm, Senti Biosciences secured an additional $10 million in investment from Celadon Partners, raising the total capital in the financing round to $47.6 million. The funds are earmarked for the development of Senti Bio’s SENTI-202 program, as well as for scaling up manufacturing and other research and development activities.

Chardan Capital Markets recently upgraded Senti Biosciences’ stock target from $10.00 to $12.00 following positive clinical trial results for SENTI-202, a treatment for relapsed/refractory hematologic malignancies. The initial data showed promising results with two out of three patients achieving complete remission.

Additionally, Senti Biosciences announced the appointment of Fran Schulz to its Board of Directors and as chair of the Board’s Audit Committee. Schulz brings over 35 years of experience from Ernst & Young, where she played a key role in the firm’s expansion and served as a founding member of its Life Sciences Practice. These developments underscore the company’s commitment to growth and innovation in its pipeline development.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.